People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Janux Therapeutics, Inc. | — | Biotechnology | Series D+ | $192.4M | $4.0B | 2020 |
| Aratana Therapeutics, Inc. | — | Pharmaceuticals | Series B | $67.3M | $1.0B | 2013 |
| Otonomy, Inc. | — | Biotechnology | Series B | $44.8M | $961.1M | 2010 |
| Arialys Therapeutics, Inc. | — | Biotechnology | Series A | $29.1M | $49.1M | 2022 |
| ReVision Therapeutics, Inc. | — | Biotechnology | Seed | $3.4M | $22.2M | 2010 |
Jay Lichter, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Lichter, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Weber | 2 | 8 |
| Tighe Reardon | 2 | 7 |
| Jay Lichter | 2 | 7 |
| Douglas Downs | 2 | 6 |
| David Rosen | 1 | 10 |
| Peter Bisgaard | 1 | 9 |
| Jeffrey Harris | 1 | 9 |
| Ed Hurwitz | 1 | 9 |
| Brian Dovey | 1 | 7 |
| Heather Preston | 1 | 6 |
| John McKearn | 1 | 6 |
| Court Turner | 1 | 6 |
| Sheila Gujrathi | 1 | 5 |
| Kevin Kinsella | 1 | 4 |
| Robert Gerber | 1 | 4 |
| Ron Meeusen | 1 | 4 |
| Steven St. Peter | 1 | 4 |
| Vickie L. Capps | 1 | 3 |
| Craig Tooman | 1 | 3 |
| Peter Thompson, M.D. | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.